Trial Profile

A Phase I/II Study of Carfilzomib in Combination With R-CHOP (CR-CHOP) for Patients With Diffuse Large B-cell Lymphoma

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 30 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aciclovir (Primary) ; Carfilzomib (Primary) ; Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Filgrastim (Primary) ; Filgrastim (Primary) ; Pegfilgrastim (Primary) ; Prednisone (Primary) ; Rituximab (Primary) ; Vincristine (Primary)
Indications Diffuse large B cell lymphoma
Focus Adverse reactions

Most Recent Events

02 May 2024 Status changed from active, no longer recruiting to completed.
12 Dec 2023 Results assessing the safety and efficacy of K in combination with R-CHOP (KR-CHOP) and the recommended phase 2 dose (RP2D) in all DLBCL patients, were presented at the 65th American Society of Hematology Annual Meeting and Exposition.
12 Jan 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com